State Street Corp Has $15.14 Million Position in CryoLife, Inc. (CRY)

State Street Corp increased its position in shares of CryoLife, Inc. (NYSE:CRY) by 5.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 758,840 shares of the medical equipment provider’s stock after buying an additional 37,279 shares during the period. State Street Corp owned 2.27% of CryoLife worth $15,143,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CRY. State of Alaska Department of Revenue grew its holdings in CryoLife by 80.8% in the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock worth $107,000 after purchasing an additional 2,407 shares during the period. First Mercantile Trust Co. grew its holdings in CryoLife by 5.6% in the second quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after purchasing an additional 291 shares during the period. Municipal Employees Retirement System of Michigan grew its holdings in CryoLife by 3.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock worth $127,000 after purchasing an additional 230 shares during the period. Creative Planning grew its holdings in CryoLife by 3.0% in the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after purchasing an additional 200 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in CryoLife by 17.7% in the second quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock worth $138,000 after purchasing an additional 1,041 shares during the period. 70.26% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently issued reports on CRY. Northland Securities reiterated a “buy” rating and set a $23.50 price objective on shares of CryoLife in a report on Monday, November 13th. TheStreet cut shares of CryoLife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Zacks Investment Research cut shares of CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Lake Street Capital lifted their price objective on shares of CryoLife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $25.00 price objective on shares of CryoLife in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $23.63.

WARNING: “State Street Corp Has $15.14 Million Position in CryoLife, Inc. (CRY)” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/11/22/state-street-corp-has-15-14-million-position-in-cryolife-inc-cry.html.

CryoLife, Inc. (NYSE:CRY) opened at $19.90 on Wednesday. The stock has a market cap of $652.42, a PE ratio of 47.56 and a beta of 0.82. CryoLife, Inc. has a twelve month low of $14.02 and a twelve month high of $24.00. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29.

CryoLife (NYSE:CRY) last issued its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. CryoLife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $44.60 million. During the same period last year, the company earned $0.13 earnings per share. The business’s revenue was down 2.9% on a year-over-year basis. sell-side analysts anticipate that CryoLife, Inc. will post 0.28 EPS for the current fiscal year.

In related news, VP David C. Gale sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $19.63, for a total transaction of $392,600.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total transaction of $76,000.00. Following the transaction, the chief accounting officer now owns 98,705 shares in the company, valued at $1,875,395. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 229,240 shares of company stock worth $4,888,065. 6.00% of the stock is owned by corporate insiders.

CryoLife Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit